• Project expansion designates target-based Development Programme

News & Views

Project expansion designates target-based Development Programme

Jan 09 2023

A neuroscience collaboration with Bristol Myers Squibb that has achieved an expansion of portfolio with two additional drug discovery projects and designated a target-based programme for further development, has triggered payments of US$ 26 million to Evotec SE (Hamburg, Germany).

Initiated in December 2016 with the goal of identifying disease-modifying treatments the partnership has leveraged Evotec’s precision medicine technologies for modality-agnostic drug discovery and development. A first programme originating from the collaboration, EVT8683, was in-licensed by Bristol Myers Squibb in September 2021, following the successful filing of an IND application with the FDA. 

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: “We are delighted to see that after six years our neuroscience collaboration with Bristol Myers Squibb continues to be highly productive across its entire value chain. This is a testament to the scientific excellence and dedication of the teams at Evotec and Bristol Myers Squibb. We are confident that the growing pipeline of promising development candidates will yield transformative therapeutic options for patients living with neurodegenerative conditions.”

More information online

Digital Edition

Lab Asia 31.2 April 2024

April 2024

In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...

View all digital editions



May 28 2024 Tel Aviv, Israel


May 28 2024 Leuven, Belgium

PREP 2024

May 28 2024 Philadelphia, PA, USA


May 29 2024 Beijing, China

ASMS Conference

Jun 02 2024 Anaheim, CA, USA

View all events